Extract
Surgical lung biopsy (SLB) in diffuse parenchymal lung disease (DPLD) has been associated with significant in-hospital mortality (16% for non-elective patients, 1.7% for elective patients, overall 6.4%) [1, 2]. Overall 30-day mortality from SLB is reported at 1.5–4.5% from case series and 2.4% from a large European database [3]. Transbronchial cryobiopsy (TBC) has been proposed as a safer alternative to SLB for diagnosis of DPLD [4]. Existing studies on TBC report immediate procedural complications, but data on mortality at 30 and 90 days is sparse [2].
Abstract
This study suggests 30- and 90-day mortality after transbronchial cryobiopsy is higher than reported, confirming concerns raised about safety in advanced diffuse lung disease. Keen attention towards patient selection and procedural planning is warranted. http://bit.ly/2ySoZNq
Footnotes
Conflict of interest: J. Pannu has nothing to disclose.
Conflict of interest: L.J. Roller has nothing to disclose.
Conflict of interest: F. Maldonado reports grants from ERBE research funding, outside the submitted work.
Conflict of interest: R.J. Lentz has nothing to disclose.
Conflict of interest: H. Chen has nothing to disclose.
Conflict of interest: O.B. Rickman has nothing to disclose.
- Received February 18, 2019.
- Accepted June 25, 2019.
- Copyright ©ERS 2019
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
